Table 2. Stimulation cycle characteristics in both groups.
  Luteal phase support p - value
Cyclogest (n=985) Cyclogest/Proluton (n=177)
Protocol Antagonist 734 (74.5%) 131 (74.0%) 0.887
Long 251 (25.5%) 46 (26.0%)
Procedure ICSI 941 (95.5%) 172 (97.2%) 0.317
IVF 44 (4.5%) 5 (2.8%)
Total gonadotropin Dose Median (IQR) 1800 (2700 - 1350) 2025 (3225 - 1225) 0.196
Number of eggs Median (IQR) 7 (10 - 5) 7 (10 - 4.5) 0.693
Number of embryos generated Median (IQR) 4 (6 - 2) 4 (6 - 2) 0.787
Number of embryos transferred 1 169 (17.2%) 35 (19.8%) 0.400
2 795 (80.7%) 140 (79.1%) 0.618
3 21 (2.1%) 2 (1.1%) 0.378
ET Day 2 287 (29.1%) 54 (30.5%) 0.712
3 582 (59.1%) 107 (60.5%) 0.733
4 48 (4.9%) 9 (5.1%) 0.904
5 68 (6.9%) 7 (4.0%) 0.142
FSH drug Recombinant FSH (Gonal-F) 528 (53.6%) 86 (48.6%) 0.218
Human menopausal gonadotropin (Merional) 397 (40.3%) 74 (41.8%) 0.708
Recombinant FSH (Gonal-F) + Human menopausal gonadotropin (Merional) 48 (4.9%) 14 (7.9%) 0.098
Recombinant FSH (Gonal-F) + recombinant LH (Lutropin alfa) 12 (1.2%) 3 (1.7%) 0.605